EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events

Pavel Burda, Alzbeta Hlavackova, Vendula Polivkova, Nikola Curik, Adam Laznicka, Jitka Krizkova, Jiri Suttnar, Pavel Klener, Katerina Machova Polakova

Molecular Metabolism · 2024

DOI: 10.1016/j.molmet.2024.102016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Metabolism, 2024. Verfasst von Pavel Burda und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hematology and Blood Transfusion, Prague, Czech Republic; Institute of Pathological Physiology, First Faculty of Medicine, Charles Unive…. Hauptthemen laut MEDLINE: Carnitine, Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Solute Carrier Family 22 Member 5. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health of the Czech Republic, Ministry of Education Youth and Sports of the Czech Republic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: A prominent, safe and efficient therapy for patients with chronic myeloid leukemia (CML) is inhibiting oncogenic protein BCR::ABL1 in a targeted manner with imatinib, a tyrosine kinase inhibitor. A substantial part of patients treated with imatinib report skeletomuscular adverse events affecting their quality of life. OCTN2 membrane transporter is involved in imatinib transportation into the cells. At the same time, the crucial physiological role of OCTN2 is cellular uptake of carnitine which is an essential co-factor for the mitochondrial β-oxidation pathway. This work investigates the impact of imatinib treatment on carnitine intake and energy metabolism of muscle cells. METHODS: HTB-153 (human rhabdomyosarcoma) cell line and KCL-22 (CML cell line) were used to study the impact of imatinib treatment on intracellular levels of carnitine and vice versa. The energy metabolism changes in cells treated by imatinib were quantified and compared to changes in cells exposed to highly specific OCTN2 inhibitor vinorelbine. Mouse models were used to test whether in vitro observations are also achieved in vivo in thigh muscle tissue. The analytes of interest were quantified using a Prominence HPLC system coupled with a tandem mass spectrometer. RESULTS: This work showed that through the carnitine-specific transporter OCTN2, imatinib and carnitine intake competed unequally and intracellular carnitine concentrations were significantly reduced. In contrast, carnitine preincubation did not influence imatinib cell intake or interfere with leukemia cell targeting. Blocking the intracellular supply of carnitine with imatinib significantly reduced the production of most Krebs cycle metabolites and ATP. However, subsequent carnitine supplementation rescued mitochondrial energy production. Due to specific inhibition of OCTN2 activity, the influx of carnitine was blocked and mitochondrial energy metabolism was impaired in muscle cells in vitro and in thigh muscle tissue in a mouse model. CONCLUSIONS: This preclinical experimental study revealed detrimental effect of imatinib on carnitine-mediated energy metabolism of muscle cells providing a possible molecular background of the frequently occurred side effects during imatinib therapy such as fatigue, muscle pain and cramps.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarnitineImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveSolute Carrier Family 22 Member 5AnimalsHumansMiceCell Line, TumorAntineoplastic AgentsEnergy MetabolismMaleProtein Kinase InhibitorsMitochondria

Stichwörter der Autor:innen

CMLCarnitineImatinibOCTN2TKI therapy side effects

Substanzen

CarnitineImatinib MesylateSolute Carrier Family 22 Member 5SLC22A5 protein, humanAntineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Institute of Hematology and Blood Transfusion, Prague, Czech Republic; Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
  • Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic; First Medical Department- Dept. of Hematology, First Faculty of Medicine and General University Hospital, Char…
  • Institute of Hematology and Blood Transfusion, Prague, Czech Republic; Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic. Electronic address: Katerina.Machova@uh…

Förderung

  • Ministry of Health of the Czech Republic
  • Ministry of Education Youth and Sports of the Czech Republic

Zitieren

APA

Burda, P., Hlavackova, A., Polivkova, V., Curik, N., Laznicka, A., Krizkova, J., Suttnar, J., Klener, P., & Polakova, K. M. (2024). Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events. Molecular Metabolism. https://doi.org/10.1016/j.molmet.2024.102016

Vancouver

Burda P, Hlavackova A, Polivkova V, Curik N, Laznicka A, Krizkova J, et al. Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events. Molecular Metabolism. 2024. doi:10.1016/j.molmet.2024.102016

BibTeX
@article{Burda2024,
  author = {Burda, Pavel and Hlavackova, Alzbeta and Polivkova, Vendula and Curik, Nikola and Laznicka, Adam and Krizkova, Jitka and Suttnar, Jiri and Klener, Pavel and Polakova, Katerina Machova},
  title = {Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events},
  journal = {Molecular Metabolism},
  year = {2024},
  doi = {10.1016/j.molmet.2024.102016}
}
Kostenlos starten →